Citigroup’s RAPT Therapeutics RAPT Stock Holding History

Citigroup’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-15,625	Closed	-$2.28M	–	6233
2022 Q2	$2.28M	Buy	+15,625	New	+$2.08M	﹤0.01%	2012

Citigroup's RAPT Position: Q1 2026 in Review

Citigroup sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 8,566 shares — an estimated $290K sold.

Citigroup first reported a position in RAPT in Q4 2019 and held it in 25 quarters. The position peaked at $2.52M in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Citigroup reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Citigroup sold 8,566 RAPT Therapeutics shares in Q1 2026, an estimated $290K.
Citigroup first reported a position in RAPT Therapeutics in Q4 2019 and held it in 25 quarters.
Citigroup's RAPT Therapeutics position peaked at $2.52M in Q4 2021.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.